Cancer and insurance: strategies, risks, and models

Cancer is a common but very heterogeneous disease.If there is such a thing as a "war" on cancer, it seems to be an attritional campaign of hand-to-hand battles along a vast front, while scientists work behind the scenes to find the fabled "silver bullet."Global cancer incidence is rising.Some projections suggest a rise of more than 30% between 2019 and 2030 (Zhao et al., 2023), with modifiable risk factors including diet, alcohol consumption, and obesity playing a substantial role; indeed, nearly half of cancer deaths have been attributed to such factors (GBD 2019 Cancer Risk Factors Collaborators, 2022).Early-onset cancers (in persons under age 50 years) are a particular concern and remain poorly understood; a recent study in England points again to obesity as a significant risk factor (Garcia-Closas et al., 2026), likely reflecting a combination of behavioral, environmental, and diagnostic factors.Drivers of cancer also appear to vary by region; in countries such as South Korea, population aging is a primary contributor to increasing cancer burden, while in others, such as parts of Africa, lifestyle and environmental risk factors are increasingly implicated (Austin, 2026).Cancer mortality is equally heterogeneous, with five-year survival ranging from around 5% in pancreatic carcinoma (Cancer Research UK, 2026b) to almost 90% in breast cancer in England (Cancer Research UK, 2026a).There have been some successes; cancer mortality has been declining in some countries, including the US (Shiels et al., 2023), reflecting improvements in screening and treatment.Overall, these observations mark a growing appreciation of underlying complexity.Interpreting them is complicated by two opposing forces operating across different ages, geographies, and stages of development.On the one hand, advances in medicine have progressively eliminated or deferred competing causes of death, effectively unmasking cancer as a natural cause of death at older ages -a competing risks phenomenon.On the other hand, new lifestyle and environmental exposures may be accelerating cancer onset in younger populations by introducing physiological drivers -a challenge of a fundamentally different, public health character.Disentangling these mechanisms is essential for understanding why cancer burdens are shifting in ways that aggregate statistics alone cannot easily explain.This epidemiological complexity -marked by diverging trends in incidence and mortality, heterogeneous risk profiles, and rapidly evolving treatment landscapes -underscores the importance of robust modeling frameworks and motivates engagement from a range of disciplines.Cancer risk means different things to different professionals.To an actuary, it is a quantity to be priced and reserved against; to an oncologist, it is a challenge to be minimized through the best available treatment; to a public health expert, it is a signal of population-level burden requiring intervention.These differing objectives bring with them different presumptions, jargon, and research traditions -a communication challenge recognized explicitly when the Institute and Faculty of